Lunit to present extensive AI evidence in breast cancer screening and density‑based risk modeling at RSNA 2025

Summary

Korean medical‑AI company Lunit announced it will showcase 14 studies at the RSNA 2025 conference, including real‑world data from Sweden showing that its Lunit INSIGHT MMG system, paired with a single radiologist, increased invasive cancer detection and reduced unnecessary recalls compared with traditional double‑reading. Additional studies from Massachusetts General Hospital and Elizabeth Wende Breast Care evaluate Lunit’s AI on digital breast tomosynthesis and on AI‑derived volumetric breast density for long‑term risk modeling, indicating that density‑informed, AI‑driven approaches can improve calibration and discrimination in risk‑adapted screening programs.